A Novel Process for Developing Fully Human Monoclonal Antibodies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Novel Process for Developing Fully Human Monoclonal Antibodies
The authors describe a process for generating high affinity, fully human antibodies in culture. Specially selected splenocytes are incubated with cytokines and low levels of antigen, yielding affinity-matured, class-switched B cells. The fully human, specific antibodies produced by these cells can then be cloned and expressed for further characterization.


Pharmaceutical Technology
pp. s28-s31

14. A. Schedl et al., Nucleic Acids Res. 20, 3073–3077 (1992).

15. A. Schedl et al., Nucleic Acids Res. 21, 4783–4787 (1993).

16. A. Schedl et al., Nature 362, 258–261 (1993).

17. L. M. Weiner, J. Immunother. 29, 1–9 (2006).

18. R. Jefferis, Adv. Exp. Med. Biol. 564, 143–148 (2005).

19. R. Jefferis and J. Lund, Chem. Immunol. 65, 111–128 (1997).

20. M. A. Coccia and P. Brams, J. Immunol. 161, 5772–5780 (1998).

21. S. M. Santini et al., J. Exp. Med. 191, 1777–1788 (2000).

22. J. M. Carballido et al., Nat. Med. 6, 103–106 (2000).

23. R. Carlsson et al., J. Immunol. 148, 1065–1071 (1992).

24. C. Lapenta et al., J. Exp. Med. 198, 361–367 (2003).

25. M. Tary-Lehmann, A. Saxon, and P. V. Lehmann, Immunol. Today 16, 529–533 (1995).

26. A. R. T. Gerritsen et al., High Throughput Bio-Layer Interferometry in Therapeutic Antibody Discovery and Development (ForteBio, 2010), http://www.fortebio.com/documents/Genmab_Screening_Europe_2010.pdf, accessed Oct. 2012.

27. Octet Biosensors Product Insert, "Streptavidin High Binding Capacity Biosensors-Kinetics and Screening Grade," (ForteBio, 2007), http://www.fortebio.com/documents/41-0046-PD_Rev_B_Streptavidin_High_Binding_PI.pdf, accessed Oct. 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
33%
Breakthrough designations
11%
Protecting the supply chain
39%
Expedited reviews of drug submissions
11%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here